Conatus
Pharmaceuticals Inc. (CNAT) was a clinical-stage biopharmaceutical
company that focused on the development of treatments for chronic
liver diseases. The company's lead product candidate was emricasan, a
first-in-class, orally active pan-caspase inhibitor that was being
developed for the treatment of nonalcoholic steatohepatitis (NASH),
liver cirrhosis, and other liver diseases.
Emricasan was
designed to inhibit the activation of caspases, which are enzymes that
play a key role in the progression of liver disease. By inhibiting
caspase activation, emricasan was intended to reduce liver cell death
and inflammation, which can contribute to the progression of liver
disease.
Conatus Pharmaceuticals conducted several clinical
trials of emricasan in patients with NASH, liver cirrhosis, and other
liver diseases. However, in 2020, the company announced that it was
winding down its operations and would be liquidating its assets. As a
result, it appears that the development of emricasan and other product
candidates has been discontinued.
Conatus Pharmaceuticals was
founded in 2005 and was based in San Diego, California. The company
was listed on the NASDAQ stock exchange under the ticker symbol CNAT.
The company's liquidation and dissolution plan was approved by its
shareholders in
|
